［18F］F-FMISO和［18F］F-FLT PET/CT双核素显像预测胰腺癌耐药性的体内研究

孙晨玮, 海汪溪, 屈骞, 席云

[18F]F-FMISO and [18F]F-FLT PET/CT dual-nuclide imaging for in vivo prediction of drug resistance in pancreatic cancer

SUN Chenwei, HAI Wangxi, QU Qian, XI Yun

图3 治疗前后双核素显像各半定量参数的ROC曲线 Note： 1st Micro PET/CT was performed before treatment. 2nd Micro PET/CT was performed after the completion of treatment. The GEM+ group received intraperitoneal injections of 1 μg/kg GEM every other day, while the GEM- group received intraperitoneal injections of 20 μl PBS every other day. The treatment was administered 6 times. For the 1st Micro PET/CT, each subgroup n=12, while for the 2nd Micro PET/CT, each subgroup n=6. a? AUC≥0.90 (AUC of ΔSUVmax-FLT in the GEM- group=0.90, AUC of ΔSUVmax-FMISO in the GEM+ group=0.94, AUC of ΔSUVmax-FLT in the GEM+ group=0.97).

Fig 3 ROC curves of semi-quantitative parameters of dual-nuclide imaging before and after treatment